Cue Biopharma has filed a patent for T-cell modulatory multimeric polypeptides that consist of two different immunomodulatory polypeptides, one of which is a variant. The patent also covers nucleic acids encoding these polypeptides and methods for modulating T-cell activity using these polypeptides. GlobalData’s report on Cue Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Cue Biopharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cue Biopharma, CAR-T cell based therapies was a key innovation area identified from patents. Cue Biopharma's grant share as of September 2023 was 9%. Grant share is based on the ratio of number of grants to total number of patents.

T-cell modulatory multimeric polypeptides with variant immunomodulatory polypeptides

Source: United States Patent and Trademark Office (USPTO). Credit: Cue Biopharma Inc

A recently filed patent (Publication Number: US20230279075A1) describes a multimeric polypeptide that has potential applications in modulating the activity of T cells. The polypeptide consists of a heterodimeric structure, with a first polypeptide containing an epitope and a first major histocompatibility complex (MHC) class I polypeptide, and a second polypeptide containing a second MHC class I polypeptide and optionally an immunoglobulin (Ig) Fc polypeptide. The polypeptide also includes at least one first immunomodulatory polypeptide, which is a CD80 polypeptide, and at least one second immunomodulatory polypeptide, which is a 4-1BBL polypeptide. The CD80 polypeptide binds to a CD28 polypeptide, while the 4-1BBL polypeptide binds to a 4-1BB polypeptide.

The patent further describes variations of the multimeric polypeptide, including the inclusion of an Ig Fc polypeptide, which can be of various types such as IgG1, IgG2, IgG3, IgG4, IgA, or IgM. The Ig Fc polypeptide has an amino acid sequence that shares at least 85% amino acid sequence identity with specific sequences listed in the patent.

The multimeric polypeptide can be produced by culturing a genetically modified host cell that contains the necessary nucleic acids encoding the polypeptides. The resulting polypeptide can then be isolated from the host cell or culture medium. The patent also suggests that the multimeric polypeptide can be used in pharmaceutical compositions for various applications, such as selectively modulating the activity of epitope-specific T cells.

Overall, this patent describes a novel multimeric polypeptide with potential applications in immunomodulation. The inclusion of CD80 and 4-1BBL polypeptides, along with MHC class I polypeptides and optional Ig Fc polypeptides, provides a platform for selectively modulating T cell activity. The patent also covers methods of producing the polypeptide and its use in pharmaceutical compositions.

To know more about GlobalData’s detailed insights on Cue Biopharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies